Investment Analysts’ Weekly Ratings Changes for Nurix Therapeutics (NRIX)

Several analysts have recently updated their ratings and price targets for Nurix Therapeutics (NASDAQ: NRIX):

• 10/13/2025 – Nurix Therapeutics was given a new $22.00 price target on by analysts at Wells Fargo & Company.
• 10/11/2025 – Nurix Therapeutics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “strong sell” rating.
• 10/10/2025 – Nurix Therapeutics was given a new $33.00 price target on by analysts at Stifel Nicolaus.
• 10/10/2025 – Nurix Therapeutics had its price target lowered by analysts at Oppenheimer Holdings, Inc. from $30.00 to $28.00. They now have an “outperform” rating on the stock.
• 10/10/2025 – Nurix Therapeutics had its price target lowered by analysts at Piper Sandler from $35.00 to $32.00. They now have an “overweight” rating on the stock.
• 10/8/2025 – Nurix Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/27/2025 – Nurix Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 8/26/2025 – Nurix Therapeutics was upgraded by analysts at Baird R W to a “strong-buy” rating.

Insiders Place Their Bets

In other news, CFO Houte Hans Van sold 5,402 shares of the company’s stock in a transaction on Friday, August 1st. The stock was sold at an average price of $11.03, for a total transaction of $59,584.06. Following the transaction, the chief financial officer owned 35,512 shares of the company’s stock, valued at $391,697.36. This represents a 13.20% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Gwenn Hansen sold 4,308 shares of the company’s stock in a transaction on Wednesday, July 30th. The shares were sold at an average price of $12.01, for a total value of $51,739.08. Following the transaction, the insider directly owned 69,023 shares in the company, valued at $828,966.23. This trade represents a 5.87% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 14,014 shares of company stock worth $163,014. Insiders own 7.40% of the company’s stock.

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.